Galmed Pharmaceuticals (NASDAQ:GLMD – Get Rating) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.08, MarketWatch Earnings reports.
Shares of NASDAQ:GLMD opened at $0.54 on Thursday. The stock has a 50 day moving average of $1.34 and a 200 day moving average of $1.77. The company has a current ratio of 6.13, a quick ratio of 6.13 and a debt-to-equity ratio of 0.01. Galmed Pharmaceuticals has a 12-month low of $0.52 and a 12-month high of $4.08.
Several research firms have recently commented on GLMD. HC Wainwright lowered shares of Galmed Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Tuesday, May 3rd. Canaccord Genuity Group reduced their price target on shares of Galmed Pharmaceuticals from $24.00 to $5.00 in a research report on Wednesday, May 4th. StockNews.com began coverage on Galmed Pharmaceuticals in a research note on Friday, May 13th. They set a “sell” rating for the company. Raymond James downgraded Galmed Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Finally, Zacks Investment Research upgraded Galmed Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, February 1st.
About Galmed Pharmaceuticals (Get Rating)
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
- Get a free copy of the StockNews.com research report on Galmed Pharmaceuticals (GLMD)
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
- The TJX Companies: It’s Not All Doom And Gloom In Retail
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Analog Devices Is Ready To Scale New Highs Despite Tech Wreck
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.